Cardiovascular Drugs Market US$ 69.23 billion by 2030: Exclusive Reports by Growth Plus Reports

NEW YORK, Sept. 1, 2022 /PRNewswire/ -- The Global Cardiovascular Drugs Market is expected to clock US$ 69.23 billion by 2030, according to the latest report published by Growth Plus Reports. Due to perpetual growth in the global incidence of cardiovascular diseases, and consistent efforts toward drug discovery and development.

The global cardiovascular drugs market has been analyzed from three perspectives: by drug class, indication, and region.

Market Driver

As the cardiac diseases are increasing there are many numerous important advancements which have been made in the past few decades, to mitigate its growing burden on the healthcare system worldwide. For, instance in January 2021 the FDA approved VERQUVO in the United States to lower the risk of cardiovascular death and heart failure associated hospitalization. The drug is also used for outpatient IV diuretics in adults with symptomatic chronic heart failure and an ejection fraction less than 45%.

Download Exclusive Sample of Report @ https://growthplusreports.com/inquiry/request-sample/cardiovascular-drugs-market/7772

Excerpts from 'By Drug Class'

According to drug class, the global cardiovascular drugs market is segmented into:

• Anti-Hypertensives
• Anti-Coagulants
• Anti-Hyperlipidemic Drugs

The anti-coagulant category has driven the market forward. As anti-coagulants lowers the risk of blood clots, they may be able to reduce artery blockage. Anti-hypertensives are used to lower blood pressure. The use of anti-hyperlipidemic medications lowers triglyceride and cholesterol levels in the body, which lowers the risk of heart attacks and strokes.

Excerpts from 'By Indication'

The global market for cardiovascular drugs is divided into four categories based on indication:

• Hypertension
• Arrhythmia
• Coronary Artery Disease
• Hyperlipidemia

The market has been dominated by the high blood pressure or hypertension segments. High salt intake, along with high caffeine intake and an unfavourable sleep cycle, are the main causes of the rising number of high blood pressure symptoms. Arrhythmia, are characterized by improperly functioning electrical impulses in the heart. Factors contributing to the growth of this disease is growing prevalence of smoking, electrolyte imbalance, and increased alcohol use.

Ask here for more customization study @ https://growthplusreports.com/inquiry/customization/cardiovascular-drugs-market/7772

Excerpts from 'By Region'

The global cardiovascular drugs market therapy has been divided into four regions based on geography:

• North America
• Europe
• Asia Pacific
• Rest of the World

North America is the leading region in the global market for cardiovascular drugs. This is due to favourable regulatory conditions, and higher spending on cardiovascular medications. Additionally, the cardiovascular drugs market in North America is further expanding as a result of the rising frequency of cardiovascular disorders. According to the CDC (Centers for Disease Control and Prevention), in the United States, heart disease claimed the lives of almost 697,000 individuals in 2020. The European market for cardiovascular drug market is characterized by increased instances of cardiac disordes, presence of many market players in this region and launch of many novel drugs. For instance, according to news released by Boehringer Ingelheim and Eli Lilly and Company in March 2022, the European Commission (EC) has authorised the marketing of Jardiance (empagliflozin) as a therapy for individuals with symptomatic chronic heart failure. With this approval, Jardiance is now the first and only drug approved for treating all adults with symptomatic chronic heart failure, including those with reduced ejection fraction. Asia Pacific cardiovascular drugs market is anticipated to grow in the forecast period due to factors such as rising body mass index (BMI), declining physical activity, a high incidence of smoking, and poor eating habits. Additionally, the region consist of high patient population, and the rate of clinical trials is also high, which is an important influencing factor for the growth of the global cardiovascular drugs market.

Excerpts from 'Competitive Landscape'

Some of the prominent companies operating in the global cardiovascular drugs market are:

• Amgen Inc
• Baxter International Inc
• Bristol-Myers Squibb Company
• F. Hoffman-La Roche Ltd
• GSK Plc
• Johnson & Johnson services, Inc
• Merck & CO., Inc. (MSD)
• Pfizer Inc
• Sanofi SA
• Bayer AG
• Lupin Ltd

Cardiovascular Drugs Market Segmentation:

Drug Class Outlook:

• Anti-Hyperlipidemics
• Anti-Hypertensives
• Anti-Coagulants

Indication Outlook:

• Hypertension
• Arrhythmia
• Coronary Artery Disease
• Hyperlipidemia

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• 'Business Profile' of Key Players

Speak to Our Expert: https://growthplusreports.com/inquiry/speak-analyst/cardiovascular-drugs-market/7772

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

Contact:
Manan Sethi
Director, Market Insights
Email: [email protected]
Phone no: +91 96545 76783
Web: https://growthplusreports.com/ 
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/1671244/Growth_Plus_Reports_Logo.jpg

SOURCE Growth Plus Reports